A quote by Nilaya Varma, Co-founder and Group CEO, Primus Partners, in a recent Forbes article mentions that the global GLP-1 therapeutics market is expected to maintain strong long-term growth, driven by continuous innovation in drug development and combination therapies. According to the analysis, the market is projected to surpass the $150 billion mark by 2030, even as revenue growth moderates from the exceptional pace witnessed in recent years.
The article further highlights that pharmaceutical companies are increasingly focusing on developing next-generation GLP-1 therapies that improve both treatment efficacy and patient safety. Continued investments in research, innovative formulations, and expanded clinical applications are expected to support sustained growth, reinforcing GLP-1 therapies as one of the most promising segments of the global pharmaceutical industry.
